Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ESH MM 2018 | UK NCRI AML17 trial update: everolimus addition for consolidation

Robert Hills • 5 Oct 2018
ESH MM 2018
Acute Myeloid Leukemia Leukemia Everolimus
AML17

Robert Hills of the University of Oxford, Oxford, UK, gives us an update on the addition of the mTOR inhibitor everolimus to consolidation therapy in the UK NCRI AML17 trial (ISRCTN55675535). Prof. Hills describes the results so far, which while not favourable for this specific combination do not rule it out as an effective option in other settings. This video was recorded at the European School of Haematology (ESH) International Conference on MM 2018, held in Mandelieu, France.

More from Robert Hills

2:24
Judging the value of a clinical trial in hem-onc
Robert Hills • 5 Oct 2018
2:17
Opinion: value of MRD as an endpoint in hem-onc clinical trials
Robert Hills • 5 Oct 2018

Related Videos

1:40
The role of CPX-351 in the AML treatment landscape & insights into the AMLSG 30-18 trial
Felicitas Thol • 19 Apr 2024
3:21
Integrating genomics and MRD in transplant decision-making for patients with AML
Jurjen Versluis • 22 Apr 2024
4:19
Blinatumomab to achieve remission and consolidation with haploSCT for pediatric ALL
Alberto Olaya-Vargas • 15 Apr 2024
3:32
Improving CAR-T therapy for ALL & lymphoma: allogeneic products & reducing CRS/ICANS
Sridhar Chaganti • 16 Apr 2024
The content of VJHemOnc is intended for healthcare professionals